InsiderClue
← All stocks

TScan Therapeutics, Inc.

TCRX Net buying
CIK 0001783328 #4673 in the set updated 21 Sep 2026
Bought (12 mo)
$145.53K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
+$145.53K
+$145.53K against sales at will

By person

2 insiders · 3 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Lynx1 Capital Management LP entity
10% owner
$145.53K (3)
—
+$145.53K
8,019,148
6.2%
$7.21M
+56.1%
Klencke Barbara
Director
—
—
—
45,000
0.035%
$40.45K
+12.5%

Individual transactions

3
Insider
Date
Role
Action
Shares
Price
Amount
Lynx1 Capital Management LP
23 Dec 2025
10% owner
Buy indirect
6,232
$0.90
$5.60K
Lynx1 Capital Management LP
22 Dec 2025
10% owner
Buy indirect
75,500
$0.90
$67.95K
Lynx1 Capital Management LP
19 Dec 2025
10% owner
Buy indirect
80,069
$0.90
$71.97K

What was left out

Form 4 filings counted 12
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 0
History held since 16 Jul 2021